Kaleido Biosciences Inc KLDO

NAS: KLDO | ISIN: US4833471000   28/04/2025
0,010 USD (+100,00%)
(+100,00%)   28/04/2025

28 februari 2022 · Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs · Persbericht

15 februari 2022 · Invaio Sciences Strengthens Its Board Of Directors With The Appointment Of Hugh Grant · Persbericht

13 oktober 2021 · Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change · Persbericht

25 mei 2021 · Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture · Persbericht

19 mei 2021 · Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening · Persbericht

30 maart 2021 · Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer · Persbericht

3 maart 2021 · Kaleido Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results · Persbericht

1 maart 2021 · Kaleido Biosciences to Present at Chardan’s 3rd Annual Microbiome Medicines Summit · Persbericht

25 februari 2021 · Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target · Persbericht

11 februari 2021 · Kaleido Biosciences Announces the Exercise of the Underwriters’ Option to Purchase Additional Shares of Common Stock · Persbericht

4 februari 2021 · Kaleido Biosciences Announces Pricing of Public Offering of Common Stock · Persbericht

3 februari 2021 · Kaleido Biosciences Announces Proposed Public Offering of Common Stock · Persbericht

20 januari 2021 · Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference · Persbericht

14 januari 2021 · Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19 · Persbericht

5 januari 2021 · Kaleido Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference · Persbericht

4 januari 2021 · Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19 · Persbericht

Mijn selecties